Tenaya Therapeutics Issues Update On Clinical Development Programs And Outlines Strategic Priorities For 2026; Aims To Build On Positive 2025 Interim TN-201 Results In H1 2026
Benzinga Newsdesk 9 months ago
News
Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCMExpects to Report
Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with
Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCM
Expects to Report One-Year Cohort 1 Data and Early Cohort 2 Data from RIDGE™-1 Study of TN-401 for PKP2-Associated ARVC in First Half of 2026
Plans to Pursue Alignment on Regulatory Pathways for Lead Gene Therapy Programs in 2026
Raised $60 Million in 4Q25 to Support Runway Through mid-2027
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today provided an update on its clinical development programs and outlined its strategic priorities for 2026.